C4 Therapeutics Enters Collaboration Agreement With Roche

April 09, 2026 — 07:52 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - C4 Therapeutics (CCCC) has entered into a new collaboration agreement with Roche (RHHBY, RO.SW, ROG.SW) to advance research in the degrader-antibody conjugate or DAC, modality. C4 Therapeutics and Roche will collaborate on two programs to develop DACs against undisclosed oncology targets exclusive to the collaboration. C4 Therapeutics will use its TORPEDOplatform to design degrader payload candidates. Roche will select and design the antibody as well as conjugate the antibody to the degrader payload. Roche will be responsible for advancing DAC candidates through preclinical and clinical development as well as commercialization.

C4 Therapeutics will receive a $20 million upfront payment for the two programs. It will receive near-term discovery milestone payments. C4 Therapeutics is eligible to receive over $1 billion in discovery, regulatory and commercial milestone payments. Also, the company is entitled to tiered royalties on future sales.

In pre-market trading on NasdaqGS, C4 shares are up 2.44 percent to $2.97.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

C4 Therapeutics Enters Collaboration Agreement With Roche

Tags

Latest Articles